Viking Therapeutics Inc

VKTXNASDAQ · USD
36.21USD-0.54 (-1.49%)
127

Viking Therapeutics Inc (VKTX) Straddle

VKTX straddle scan found 317 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 61.9%.

Read more

Trading a VKTX straddle lets you take a pure volatility position on Viking Therapeutics Inc without committing to a direction. Viking Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate VKTX straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on VKTX profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Viking Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the VKTX straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

The company was incorporated in 2012 and is headquartered in San Diego, California.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the VKTX straddle is the cleanest expression of that view. Our scanner prices every VKTX straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a VKTX straddle into a catalyst or short a VKTX straddle to harvest decay, the options straddle setups that matter are all in one place.

Sep 25, 202655.00$12.68241%61.9%$67.68$42.320
Jan 15, 202795.00$53.3311441%57.6%$148.33$41.680
Jan 15, 2027120.00$78.4011441%57.4%$198.40$41.6150
Jan 15, 2027110.00$68.4311441%57.3%$178.43$41.580
Jan 15, 2027100.00$58.6311441%56.9%$158.63$41.380
Jan 15, 202785.00$43.7411441%56.9%$128.74$41.27314
Jan 15, 202790.00$48.7011441%56.8%$138.70$41.300
Sep 25, 202650.00$8.00241%56.8%$58.00$42.000
Jan 15, 2027105.00$63.6811441%56.8%$168.68$41.330
Sep 25, 202649.00$7.02241%56.5%$56.02$41.990

As of September 24, 2026

Find the right straddle before volatility moves

Track VKTX straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial